Professional Documents
Culture Documents
HYpertension
in the
Very Elderly
Trial
N. Beckett, R. Peters, A. Fletcher, C. Bulpitt
on behalf of the HYVET committees and
investigators
ClinicalTrials.gov: NCT00122811
Disclosure Information
Disclosure Information…
The following relationships exist related to this
presentation:
Dr . Nigel Beckett MD University Salaries supported by
Dr. Ruth Peters PhD Servier/British Heart Foundation
Prof Astrid Fletcher PhD No Support
Prof Christopher Bulpitt MD Imperial College Consultancy fees
supported by Servier
Blood Pressure & The Very
Elderly (aged 80 or more)
• Epidemiologic population studies suggest
better survival with higher levels of blood
pressure
• Worse survival reported in hypertensives
with SBP levels below 140 mmHg (Oates et al.
2007)
Primary Endpoint:
All strokes (fatal and non-fatal)
Placebo Active
1912 1933
Blood Pressure:
Sitting SBP (mmHg) 173.0 173.0
Sitting DBP (mmHg) 90.8 90.8
Orthostatic Hypotension‡ 8.8% 7.9%
Isolated Systolic Hypertension 32.6% 32.3%
Placebo Active
Current smoker 6.6% 6.4%
Diabetes
(Known DM/ DM treatment/glucose>11.1mmo/l)
6.9% 6.8%
150
Blood Pressure (mmHg)
140
Placebo
130
100
6 mmHg
90
80
70
0 1 2 3 4 5
Follow-up (years)
All stroke
(30% reduction)
Placebo
P=0.055 Indapamide
SR
±perindopril
Placebo
IndapamideSR ±perindopril
Total Mortality
(21% reduction)
Placebo
P=0.019 Indapamide
SR
±perindopril
Placebo
IndapamideSR ±perindopril
Fatal Stroke
(39% reduction)
Placebo
Indapamide
P=0.046
SR
±perindopril
Placebo
IndapamideSR ±perindopril
Heart Failure
(64% reduction)
Placebo
P<0.0001
IndapamideSR
±perindopril
Placebo
IndapamideSR ±perindopril
ITT – Summary
HR 95% CI
All Stroke 0.70 (0.49, 1.01)
Stroke Death 0.61 (0.38, 0.99)
All cause 0.79 (0.65, 0.95)
mortality
NCV/Unknown 0.81 (0.62, 1.06)
death
CV Death 0.77 (0.60, 1.01)
HR 95% CI P